Activity of Plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece

作者：Galani Irene^*; Souli Maria; Daikos George L; Chrysouli Zoi; Poulakou Garyphalia; Psichogiou Mina; Panagea Theofano; Argyropoulou Athina; Stefanou Ioanna; Plakias George; Giamarellou Helen; Petrikkos George

来源：Journal of Chemotherapy, 2012, 24(4): 191-194.

DOI：10.1179/1973947812Y.0000000015

• Aminoglycosides
• Multidrug resistant
• VIM
• KPC

The in vitro activity of plazomicin was evaluated against 300 multidrug resistant (MDR) (carbapenemase and/or ESBL-producing) isolates from four hospitals in Athens, an area where carbapenemase-producing organisms are endemic. Most of the isolates were also resistant to the legacy aminoglycosides with the MIC50/MIC90 to tobramycin, amikacin and gentamicin being 32/%26gt;32, 32/%26gt;32 and 4/%26gt;8 mu g/ml, respectively. ACHN-490 retained activity (MICs %26lt;= 4 mu g/ml) against all isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. tested with MIC50 and MIC90 of 1 and 2 mu g/ml, respectively, irrespective of their MDR phenotype and it represents a promising alternative for the treatment of the most problematic Gram-negative pathogens.

• 出版日期2012-8